AARTIDRUGS2024-10-012024-12-31 AARTIDRUGS2024-10-012024-12-31 AARTIDRUGS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member AARTIDRUGS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member AARTIDRUGS2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524348 AARTIDRUGS NOTLISTED Aarti Drugs Limited Equity 2024-04-01 2025-03-31 2025-01-29 2025-01-22 INR Lakhs Third quarter 12:00:00 16:20:00 2025-01-29 2025-01-29 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Audited Consolidated 5566000000.00 119000000.00 5685000000.00 3697900000.00 141100000.00 -325100000.00 277600000.00 90700000.00 138000000.00 1157200000.00 5177400000.00 507600000.00 0.00 507600000.00 120000000.00 16700000.00 136700000.00 0.00 370900000.00 0.00 0.00 0.00 0.00 370900000.00 -4600000.00 366300000.00 370500000.00 467000.00 366100000.00 235000.00 912700000.00 10 4.06 4.06 0.00 0.00 4.06 4.06 1.The above results for the Quarter & Period ended 31st December, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 29th January, 2025.  2.The Board of Directors have declared interim Dividend of Rs 1.00/-( Rupee one)  per Equity Share of Rs. 10/- each (10%) amounting to Rs.9,12,70,000/- for the Period ended 31st December,2024. 3.Other Income includes Rs. 1,134.03 lakhs , comprising interest on income tax refunds determined and receivable from the Income Tax Department. These amounts arise from the disposal of pending appeals with CIT(A) and orders giving effect passed by tax authorities for AY 2010-11 to AY 2020-21.The Company has filled an appeal to ITAT for the further relief and simultaneously the department has also appealed before Tribunal, which are pending to be heard by the Tribunal as of now. 4.The company has completed the buyback of 6,65,000 equity shares of face value of Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors’ fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.)(“Buyback Size”) on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each. 5. As on December 31, 2024 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA. 6.Company has only one business segment i.e. pharmaceuticals. 7. Figures for the previous Quarter have been regrouped or rearranged wherever necessary. 8.The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.co.in and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. FOR AARTI DRUGS LIMITED Sd/- Prakash M. Patil DIN: 00005618 (Chairman, Managing Director & CEO) Place: Mumbai Date: 29th January, 2029 Single segment 2024-04-01 2024-12-31 Audited Consolidated 17102700000.00 144900000.00 17247600000.00 10631600000.00 612200000.00 -191800000.00 807500000.00 267100000.00 409000000.00 3305800000.00 15841400000.00 1406200000.00 0.00 1406200000.00 308100000.00 44800000.00 352900000.00 0.00 1053300000.00 0.00 0.00 0.00 0.00 1053300000.00 3000000.00 1056300000.00 1053000000.00 300000.00 1055900000.00 453000.00 912700000.00 10 11.54 11.54 0.00 0.00 11.54 11.54 Other Expenses 1157200000.00 Other Expenses 3305800000.00